Breast cancer survivors may have increased risk of thyroid cancer
the ONA take:
According to preliminary findings presented at the annual meeting of the Endocrine Society in San Diego, California, researchers at Columbia University Medical Center in New York City have found that female breast cancer survivors may be at an increased risk for developing thyroid cancer.
For the study, researchers analyzed government data from over 700,000 American women treated for breast cancer.
They found that women had a higher-than-average risk for developing thyroid cancer, mostly within 5 years of the breast cancer diagnosis.
The researchers estimated that a 40-year-old female breast cancer survivor's risk of developing thyroid cancer in the next 10 years was 16% and 12% for a 50-year-old woman, compared with 0.3% for the average U.S. woman.
The findings do not make it clear what causes the association, but it may be related to the thyroid gland being exposed to radiation treatment for breast cancer. In general, the incidence of thyroid cancer is increasing in the United States, possibly due to better detection with the increasing use of thyroid ultrasound.
Female breast cancer survivors may be at an increased risk for developing thyroid cancer.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|